In my opinion no capital raising is to be expected. Their debt levels are a bit high especially with the new debt from SOL but it should be considered manageable at the present moment. Profits should be OK to cover debt and interest.
"Expectations of a modest Operating EBITDA profit for 1H2019 compared to an Operating EBITDA loss of $1.8 million for the prior corresponding period despite the incurrence of non‐recurring legal expenses and an increased investment in research and development."
Last year result was a loss around 5 million.
- Forums
- ASX - By Stock
- PAL
- News: PAL Palla Pharma Enters Into New Multi‐Year Supply Agreement With A European Customer
News: PAL Palla Pharma Enters Into New Multi‐Year Supply Agreement With A European Customer, page-9
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online